EGFR and non-small cell lung carcinoma: Proof of concept experiments in 2D cultures demonstrated specific FDG uptake by NSCLC cell lines which reduced FDG retention upon treatment in EGFR-mutant and therefore gefitinib-sensitive HCC827 cells (54, 55, 56, 57, 32) but not in the resistant A549 cells.